Stanford cancer-fighting spinout to Genentech: 'Don't eat me'
A Peninsula startup focusing on a hijacked "don't eat me" signal sent by cancer cells to the immune system will work with Genentech Inc. to take an experimental drugs into two clinical trial programs.
Forty Seven Inc., a Menlo Park-based spinout of from the Stanford University labs of Irv Weissman, also said Thursday that it cut a deal with Germany's Merck KGaA for another study in humans.
The financial value of both deals and how research and development costs will be split wasn't disclosed b y…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Germany Health | Health Management | Men | Merck | Study